Sharing Progress in Cancer Care posted on LinkedIn:
“Repurposing a drug with a known mode of action to work in a different disease setting can offer a faster and cheaper way to bring new treatment options to patients in need.
Sophie Fessl looks at a proposed revision to the EU’s pharmaceutical regulation that could help unleash that strategy.
Read the full article on Cancerworld.”
Source: Sharing Progress in Cancer Care/LinkedIn
Sophie Fessl is a Science Communication Professional. She is the Head of Communications at Institute of Molecular Biotechnology and Gregor Mendel Institute. She was also a science writer at IST Austria.